Navigation Links
Gene fusion discovery may lead to improved prostate cancer test
Date:4/9/2009

ch and a pathologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

Dr. Rubin's team is already working with a company to develop a urine test for prostate cancer using a chromosome-based gene fusion called TMPRSS2-ERG that the team discovered previously while working with members of Dr. Arul Chinnaiyan's research group at the University of Michigan. Dr. Rubin anticipates that the newly discovered SLC45A3-ELK4 gene fusion may be added to that urine test in the future to increase its accuracy and also to potentially help determine the level of response to certain non-surgical systemic treatments. The TMPRSS2-ERG urine test is being evaluated in multiple early clinical trials in the United States and Europe.

Novel Gene Fusion Sheds Light on How Cancer Works

Unlike the gene fusions previously found in cancers, which arise when two chromosomes join together in an abnormal way, the new fusion occurs when the genes are being copied into RNA. The two genes, SLC45A3 and ELK4, reside next to one another on the chromosome in normal and prostate cancer cells. However, when the genes are copied into RNA in the prostate cancer cells, they frequently generate a single RNA message that fuses information from both genes. Ongoing work is exploring the potential biologic implications of this discovery. However, the diagnostic implications are more immediate because these types of genetic chimera occur at significantly higher levels in abnormal tumor cells.

"We think this type of gene fusion might be a common mechanism in cancer," Dr. Rubin says. "This expands our understanding of how tumor cells may hijack androgen-regulated genes with neighboring genes and effectively alter its regulation. This may be a way tumors gain a competitive advantage."


'/>"/>

Contact: John Rodgers
jdr2001@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Direct Anesthetic Infusion Helps Colorectal Cancer Patients
2. Controversial Anemia Drug Doesnt Cut Need for Transfusions
3. Additional Top Tier Institutions Implement Mediwares HCLL(TM) Transfusion Management Software
4. Survey reveals ignorance and confusion about cancer amongst the elderly
5. Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
6. New transfusion rules restrict donations from previously pregnant women
7. Leukocyte reduction seen as significant advance in transfusion medicine
8. Mediwares Transfusion Management Software Adopted by Four Additional Tenet Hospitals
9. Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain
10. DNC: Romneys Health Care Confusion Continues
11. Infusion Therapy Raises Death Risk for Some Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... Santa Clara, CA (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 ... The National Football League’s biggest day each year is the Super Bowl. In the ... buildup that takes place from the host venue. The 2016 Super Bowl game will mark ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last ... by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , ... are customizable. The best part: whenever a product is purchased, the Meso Foundation ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics ... this week. Zeltiq Aesthetics released this new applicator in the United States as ... treating the outer thighs. The original applicator required a 2 hour treatment time. ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... 28 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ... and commercialization of proprietary products that address important therapeutic ... Glenn A. Oclassen, President & Chief Executive Officer, is ... Science Conference in New York City on Wednesday, June ...
... LaboratoryALBUQUERQUE, N.M., May 28 Exagen Diagnostics, Inc. today ... to assist physicians with diagnosing Irritable Bowel Syndrome (IBS) ... tests at Digestive Disease Week 2009 in Chicago, May ... identifies patients with IBS, while the eXaIBD ...
... to Vote WHITE Proxy Card to Re-Elect Highly-Qualified ... Opposition SlateTUCSON, Ariz., May 28 The Providence ... announced that it has issued the following letter ... to vote at the upcoming 2009 Annual Meeting ...
... Quality, Cutting CostsSILVER SPRING, Md., May 28 ... outcomes management systems, today issued a white paper ... Congress to require consumer-driven outcomes management as a ... industry. "Consumer-Driven Outcomes Management: A New Paradigm for ...
... May 28 NXGen Holdings, Inc. (Pink Sheets: ... is entering the $17.5 Billion Household and Industrial ... Green Bridge Industries, Inc., a company which manufactures ... NXGen Holdings, Inc. acquired Green Bridge Industries in ...
... Data To Be Presented at 2009 ASCO Annual ... Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic ... Host Analyst and Investor Briefing to Discuss Data ... Calif., May 28 Poniard Pharmaceuticals, Inc. (Nasdaq: ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009 2Health News:Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009 3Health News:Exagen Launches New Diagnostic Assays for Bowel Disease at Digestive Disease Week Conference 2Health News:Providence Service Corporation Issues Letter to Stockholders 2Health News:Providence Service Corporation Issues Letter to Stockholders 3Health News:Providence Service Corporation Issues Letter to Stockholders 4Health News:Providence Service Corporation Issues Letter to Stockholders 5Health News:Providence Service Corporation Issues Letter to Stockholders 6Health News:Providence Service Corporation Issues Letter to Stockholders 7Health News:Providence Service Corporation Issues Letter to Stockholders 8Health News:Providence Service Corporation Issues Letter to Stockholders 9Health News:MyOutcomes Urges Government Leaders to Employ Consumer-Driven Outcomes Management in Reforming Behavioral Health System 2Health News:MyOutcomes Urges Government Leaders to Employ Consumer-Driven Outcomes Management in Reforming Behavioral Health System 3Health News:NXGen Holdings, Inc. Enters the $17.5 Billion Household and Industrial Cleaning Products Industry through the Acquisition of Green Bridge Industries, Inc. 2Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 2Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 3Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 4Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 5Health News:Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer 6
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... , ENGLEWOOD, Colo., Dec. 7 ... DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting (MCM). ... safety and pharmacy efficiency through the management of IV ... into current pharmacy practice and techniques, while providing a ...
... , CARLSBAD, Calif., Dec. 7 Genoptix, Inc. (Nasdaq: ... the Company,s participation at the Deutsche Bank 2009 MedTools Investor ... Mass. on December 9-10, 2009. , Genoptix,s EVP ... the Company on Wednesday, December 9, 2009. He will ...
Cached Medicine Technology:Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2
... Advanced Magnetics' contrast agent for use with MRI ... the first organ-specific MRI contrast agent to be ... agent is taken up by macrophages found only ... tumors. The liver is a principal site for ...
... new Contrast Agent for Ultrasonography ... stabilized SF6 microbubbles. The size ... 1 and 10 m, and ... and 5 x 108 per ...
... VISIPAQUE is the only isosmolar contrast medium (IOCM) ... to that of blood, VISIPAQUE was designed for ... only contrast medium formulated with sodium and calcium ... VISIPAQUE received FDA approval for use in children ...
... (iopromide) injection is a nonionic, iodinated, ... administration. Introduced in the U.S. in ... in Europe, ULTRAVIST today is ... has established a positive clinical experience ...
Medicine Products: